

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

April 16, 2021

In The Matter of	:	
	:	
Immune Pharmaceuticals Inc.	:	ORDER OF SUSPENSION
	:	OF TRADING
File No. 500-1	:	
	:	

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Immune Pharmaceuticals Inc. (“IMNPQ” or “the Company”) (CIK No. 0001208261), a Delaware corporation last located in Fort Lee, New Jersey, because it is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-Q for the period ending September 30, 2018, and because of questions regarding the accuracy of publicly available information in the marketplace concerning IMNPQ, including current reports on Form 8-K filed on April 12, 2021 and April 13, 2021; the Company’s assets; the Company’s current financial condition; and recent, increased trading activity in the securities of IMNPQ despite its status as a debtor in a Chapter 7 bankruptcy proceeding. As of April 14, 2021, the common stock of IMNPQ was quoted and traded on OTC Link whose parent company is OTC Markets Group, Inc., had eight market makers, and was eligible for the “piggyback” exception of Rule 15c-2-11(f)(3) under the Securities Exchange Act of 1934.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed Company.

THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on April 19, 2021 through 11:59 p.m. EDT on April 30, 2021.

By the Commission.

Vanessa A. Countryman
Secretary